Imatinib and Trametinib for KRAS-mutated Solid Tumor

NCT06962254 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor Cancer

Interventions

DRUG: Imatinib
DRUG: Trametinib

Sponsor

China Medical University Hospital